Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Brepocitinib MR vs IR Tablets in Healthy Participants
NCT03765554Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jan 2019
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of brepocitinib in inflammatory bowel disease (IBD) (2 arms), sponsored by Pfizer. Primary endpoints: Maximum Observed Plasma Concentration at 48 hours, Area under the plasma concentration-time curve from time zero to the last measured concentration at 48 hours and 2 more. Started Jan 2019; status: completed.
02
Drugs
brepocitinib
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT03765554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03765554.